Employees: 11 (2023.0)Legal category: 5485Size: PMECreation date: 1988-09-01 (37 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PORT-SAINT-LOUIS-DU-RHONE (13230), Bouches-du-Rhone
SELARL PHARMACIE DU STADE : revenue, balance sheet and financial ratios
SELARL PHARMACIE DU STADE is a French company
founded 37 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PORT-SAINT-LOUIS-DU-RHONE (13230),
this company of category PME
shows in 2025 a revenue of 3.5 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE DU STADE (SIREN 347889941)
Indicator
2025
2024
2023
2022
2021
2020
2018
2017
2016
Revenue
3 478 826 €
N/C
N/C
N/C
N/C
1 221 419 €
N/C
N/C
1 076 231 €
Net income
252 639 €
371 997 €
279 520 €
261 085 €
296 588 €
138 532 €
57 645 €
79 347 €
57 502 €
EBITDA
370 796 €
N/C
N/C
N/C
N/C
191 840 €
N/C
N/C
60 345 €
Net margin
7.3%
N/C
N/C
N/C
N/C
11.3%
N/C
N/C
5.3%
Revenue and income statement
In 2025, SELARL PHARMACIE DU STADE achieves revenue of 3.5 M€. Over the period 2016-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +13.9%. After deducting consumption (2.5 M€), gross margin stands at 1.0 M€, i.e. a rate of 29%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 371 k€, representing 10.7% of revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 253 k€, i.e. 7.3% of revenue. This profit can be retained or distributed to shareholders.
Revenue (2025)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
3 478 826 €
Gross margin (2025)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
1 006 703 €
EBITDA (2025)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
370 796 €
EBIT (2025)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
328 887 €
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
252 639 €
EBITDA margin (2025)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
10.7%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 110%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 43%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 5.1 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 8.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
110.233%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
42.551%
Cash flow / Revenue (2025)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
8.452%
Repayment capacity (2025)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
5.094
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL PHARMACIE DU STADE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2020
2021
2022
2023
2024
2025
Debt ratio
30.387
10.081
0.468
20.516
49.448
24.664
155.741
135.759
110.233
Financial autonomy
61.771
73.463
82.297
66.51
53.664
64.358
34.577
38.155
42.551
Repayment capacity
4.315
None
None
1.2
None
None
None
None
5.094
Cash flow / Revenue
3.319%
None%
None%
11.473%
None%
None%
None%
None%
8.452%
Sector positioning
Debt ratio
110.232025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average
In 2025, the debt ratio of SELARL PHARMACIE DU STADE (110.23) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
42.55%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average
In 2025, the financial autonomy of SELARL PHARMACIE DU STADE (42.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
5.09 years2025
2025
Q1: 0.51 years
Med: 2.46 years
Q3: 6.17 years
Average
In 2025, the repayment capacity of SELARL PHARMACIE DU STADE (5.09) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 209.45. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.5x. Danger: operating income does not cover interest charges, unsustainable situation.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
209.452
Interest coverage (2025)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable 1.5-3 : Acceptable < 1.5 : Risk
0.547
Liquidity indicators evolution SELARL PHARMACIE DU STADE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2020
2021
2022
2023
2024
2025
Liquidity ratio
151.831
144.341
151.663
224.08
260.247
270.058
238.979
258.99
209.452
Interest coverage
9.736
None
None
0.673
None
None
None
None
0.547
Sector positioning
Liquidity ratio
209.452025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Good-6 pts over 3 years
In 2025, the liquidity ratio of SELARL PHARMACIE DU STADE (209.45) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
0.55x2025
2025
Q1: 0.0x
Med: 1.91x
Q3: 5.98x
Average
In 2025, the interest coverage of SELARL PHARMACIE DU STADE (0.6x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 9 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 41 days. Excellent situation: suppliers finance 32 days of the operating cycle (retail model). Inventory turnover is 20 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 33 days of revenue, i.e. 315 k€ to permanently finance. Over 2016-2025, WCR increased by +141%, requiring additional financing.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
314 973 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
9 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
41 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
20 j
WCR in days of revenue (2025)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
33 j
WCR and payment terms evolution SELARL PHARMACIE DU STADE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2020
2021
2022
2023
2024
2025
Operating WCR
130 751 €
0 €
0 €
295 986 €
0 €
0 €
0 €
0 €
314 973 €
Inventory turnover (days)
37
0
0
36
0
0
0
0
20
Customer payment term (days)
5
0
0
22
0
0
0
0
9
Supplier payment term (days)
48
0
0
82
0
0
0
0
41
Positioning of SELARL PHARMACIE DU STADE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE DU STADE is estimated at
2 867 287 €
(range 1 733 064€ - 4 073 661€).
With an EBITDA of 370 796€, the sector multiple of 7.7x is applied.
The price/revenue ratio is 0.61x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1733k€2867k€4073k€
2 867 287 €Range: 1 733 064€ - 4 073 661€
NAF 5 année 2025
Valuation detail by method
Ajustez les pondérations selon votre analyse
EBITDA Multiple50%
370 796 €×7.7x
Estimation2 862 658 €
1 443 626€ - 4 167 432€
Revenue Multiple30%
3 478 826 €×0.61x
Estimation2 111 062 €
1 555 255€ - 2 434 974€
Net Income Multiple20%
252 639 €×15.9x
Estimation4 013 201 €
2 723 377€ - 6 297 264€
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE DU STADE with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE DU STADE
What is the revenue of SELARL PHARMACIE DU STADE ?
The revenue of SELARL PHARMACIE DU STADE in 2025 is 3.5 M€.
Is SELARL PHARMACIE DU STADE profitable?
Yes, SELARL PHARMACIE DU STADE generated a net profit of 253 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE DU STADE ?
The headquarters of SELARL PHARMACIE DU STADE is located in PORT-SAINT-LOUIS-DU-RHONE (13230), in the department Bouches-du-Rhone.
Where to find the tax return of SELARL PHARMACIE DU STADE ?
The tax return of SELARL PHARMACIE DU STADE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE DU STADE operate?
SELARL PHARMACIE DU STADE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart